

Aviso de Derechos para emisoras del

FECHA: 21/10/2024



BOLSA MEXICANA DE VALORES, S.A.B DE C.V, INFORMA:

FOLIO DE REFERENCIA DEL EVENTO CORPORATIVO	244339
FOLIO DE REFERENCIA INDEVAL	759184C003
TIPO DE MENSAJE	Replace
COMPLETO / INCOMPLETO	INCOMPLETE
CONFIRMADO / NO CONFIRMADO	UNCONFIRMED

CLAVE DE COTIZACIÓN	BNOX
RAZÓN SOCIAL	BIONOMICS LIMITED
SERIE	N
ISIN	US09063M2052
MERCADO PRINCIPAL	NASDAQ

TIPO DE EVENTO	EXCHANGE
-----------------------	----------

MANDATORIO / OPCIONAL / VOLUNTARIO	Mandatory
---	-----------

OPCIÓN	1
TIPO	Security
DEFAULT	true

TRANSACCIÓN	Securities Movement
CREDIT / DEBIT	Debit

Aviso de Derechos para emisoras del

FECHA: 21/10/2024

VALORES A RECIBIR	US09063M2052
TRANSACCIÓN	Securities Movement
CREDIT / DEBIT	Credit

RATIO	NewToOld
	1 / 8
VALORES A RECIBIR	
	UKWN
DISPOSICIÓN FRACCIONES	RoundUp

NOTAS DEL EVENTO CORPORATIVO
NOTA

(10/10/2024)

US SEC CA 0046 Bionomics Limited SCHEDULE 14A Proposed Re.domiciliation from Australiato Delaware Your Vote is Very Important The board of directors of Bionomics Limited, an Australian corporation (Bionomics), has approvedand declared advisable a re. domiciliation (the Re.domiciliation) of Bionomics from Australia to Delaware via a scheme of arrangement (the Scheme) under Australian law. Accordingly, Bionomics has entered intoa Scheme Implementation Agreement,dated October 1, 2024 (the Agreement), with Neuphoria Therapeutics Inc., a Delaware corporation (Neuphoria) that was recently establishedto effect the re. domiciliation. Under the terms of the Agreement, Neuphoria will acquire 100PCT of the outstanding ordinary shares in Bionomics (the Bionomics Shares), including Bionomics Shares represented by American Depositary Shares, each of which represents 180 Bionomics Shares (Bionomics ADSs). The Agreement is subject to customary closing conditions, including approval ofthe Scheme by Bionomics shareholders and the Supreme Court of New South Wales or such other Australian court of competent jurisdiction (theCourt).

If the Scheme is approvedby Bionomics shareholders and theCourt, then all outstanding Bionomics Shares will be transferred to Neuphoria and the holders of Bionomics Shares as of the record date forthe Scheme (the Record Date and such holders, the Scheme Participants) will receive one share of commonstock of Neuphoria (Neuphoria Share) for every 1,440 Bionomics Shares owned. Holders of Bionomics ADSs (ADS Holders) will receive one Neuphoria Share for every 8 BionomicsADSs held. Upon completion of theScheme, Bionomics will become a wholly owned subsidiary of Neuphoria,with Neuphoria becoming the successor issuer of Bionomics. It is anticipated that Neuphoria Shares will trade on Nasdaq under the ticker symbol NEUP . Bionomics is sending youthe accompanying proxy statement to ask you to attend a special meeting of Bionomics shareholders (the Scheme Meeting), or to vote your shares by proxy, to approve the Re.domiciliation pursuant to the Schemeand as contemplated by the Agreement.

(04/10/2024)

US SEC CA 0023 BIONOMICS LIMITED 8.K Bionomics Limited announces intention to re.domicile to the United States On October 1, 2024, Bionomics Limited, an Australian corporation (gBionomics h),and Neuphoria Therapeutics Inc., aDelaware corporation (gNeuphoria h), entered into a Scheme Implementation Agreement to re.domicile fromAustralia to the U.S. state of Delaware pursuant to a Scheme of Arrangement under Australian law. Upon completion of the Scheme of Arrangement, Bionomics would become a wholly.owned subsidiary of Neuphoria. Under the Scheme of Arrangement. holders of ordinary shares in Bionomicswill receive one share of common stock in Neuphoria for every 1,440 ordinary shares of Bionomics held asof record date and holders of American Depositary Shares (gADSs h) ofBionomics will receive one share of common stock in Neuphoria for every 8 ADSs held in Bionomics as of the record date. The implementationof the Scheme of Arrangement is subject to customary conditions, including the approval of Bionomics shareholders and an Australian court aswell as other regulatory approvals. Details of the terms and conditions are set out in the Scheme Implementation Agreement, which is attached as Exhibit 2.1 to this Form 8.K.Adelaide, Australia and Cambridge, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) Bionomics Limited (Nasdaq. BNOX) (Bionomics or the Company), a clinical.stage biotechnology companydeveloping novel, potential first.in.class, allosteric ion channel modulators to treat patients suffering from serious central nervous system disorders with high unmet medical need, today announced its intention to re.domicile from Australia

FECHA: 21/10/2024

to the United States via a proposed scheme of arrangement between Bionomics and its shareholders (the Scheme) that will be governed by Australian law. Implementation of the Scheme is subject to approval of Bionomics shareholders as well as regulatory and court approvals. Bionomics is an Australian corporation and its ordinary shares, in the form of American Depositary Shares (ADSs), have been trading in the United States since listing on the Nasdaq Global Market in December 2021. Each ADS represents 180 ordinary shares of Bionomics. Should the Scheme be approved by Bionomics shareholders and an Australian court, all shareholders of Bionomics will receive a proportionate number of shares of common stock in Neuphoria Therapeutics Inc. (Neuphoria), a new parent company that was incorporated in the U.S. State of Delaware for purposes of the re-domiciliation. Neuphoria would become the successor issuer to Bionomics and the Neuphoria shares would be listed on Nasdaq, replacing the ADSs of Bionomics. Rationale for the re-domiciliation Until July 1, 2024, Bionomics qualified as a foreign private issuer (as defined in Rule 405 under the U.S. Securities Act of 1933) and, as a result, was able to take advantage of certain reduced disclosure and other requirements as an SEC registrant with securities listed on Nasdaq. Effective July 1, 2024, Bionomics no longer qualified as a foreign private issuer and, for this and other reasons, Bionomics' board of directors (the Board) has approved a plan to re-domicile Bionomics from Australia to Delaware. A re-domiciliation would eliminate significant Australian compliance costs, including avoiding the need to prepare financial statements in accordance with International Financial Reporting Standards as well as U.S. generally accepted accounting principles. In addition, the Board believes that the re-domiciliation has the potential to provide many other benefits to Bionomics and its shareholders, including: increased alignment with prominent U.S. pharmaceutical companies, thus enhancing group visibility and reputation within the industry; a U.S. corporate structure that should increase the company's attractiveness to potential strategic investors, merger partners or acquirers; improved marketability with U.S. institutional investors; increased attractiveness to a broader U.S. investor pool who previously could not invest in non-U.S. companies; and a simplified corporate structure that should reduce administrative and compliance costs. The Board is excited to enact this landmark unanimous decision in conjunction with our key shareholders and other stakeholders. It is a decision made with the intention to maximize shareholder value. By committing our presence to the United States, we believe that our Company's visibility to international investors will increase markedly, partly due to our value proposition compared to similar emerging biotech companies with a presence in North America, as said Spyros Papapetropoulos, M.D. Ph.D., Bionomics CEO. He also noted that very few Australian brokers can trade ADSs, however post the re-domiciliation, most online trading platforms facilitate direct market access to trading U.S. shares. We look forward to providing ongoing guidance to our shareholders over the coming months prior to the anticipated shareholder vote in late November 2024.